Recent earnings from Eli Lilly and Company (LLY) and Novo Nordisk (NVO) highlight the demand for GLP-1 drugs and why not all GLP-1 providers may be created equal.
Yahoo Finance senior healthcare reporter Anjalee Khemlani discusses both companies’ earnings results, with Eli Lilly seeing strong sales of its GLP-1 drugs Mounjaro and Zepbound. Khemlani also takes a look at some of the other pharmaceutical companies in the GLP-1 space.
#youtube #news #stockmarket
About Yahoo Finance:
Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.
– Get the latest news and data at finance.yahoo.com
– Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)
– Follow Yahoo Finance on social:
X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/company/yahoo-finance
source
